Cutia Therapeutics (HKG:2487)
Hong Kong · Delayed Price · Currency is HKD 0.6950
+0.0150 (2.21%)
Nov 3, 2026, 3:56 PM HKT
Cutia Therapeutics Revenue
Cutia Therapeutics had revenue of 62.71M CNY in the half year ending June 30, 2026, a decrease of -34.38%. This brings the company's total for the last twelve months to 332.58M, up 32.85% year-over-year. In the year 2025, Cutia Therapeutics had annual revenue of 336.15M with 20.22% growth. That makes Cutia Therapeutics the 28,155th largest company in the world by revenue and 1,674th in Hong Kong.
Revenue (ttm)
332.58M CNY
Revenue Growth
+32.85%
P/S Ratio
0.66
Revenue / Employee
1.24M CNY
Employees
268
Market Cap
259.35M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 336.15M | 56.54M | 20.22% |
| Dec 31, 2024 | 279.62M | 141.99M | 103.17% |
| Dec 31, 2023 | 137.62M | 126.26M | 1,110.83% |
| Dec 31, 2022 | 11.37M | 9.33M | 457.70% |
| Dec 31, 2021 | 2.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Kintor Pharmaceutical | 90.90M |
| China Regenerative Medicine International | 86.40M |
| Wuhan YZY Biopharma | 67.26M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |
Cutia Therapeutics News
- 2 months ago - Cutia Therapeutics Quarterly report: H1 2026 - Filings
- 2 months ago - Cutia Therapeutics Earnings release: H1 2026 - Filings
- 7 months ago - Cutia Therapeutics Annual report: H2 2025 - Filings
- 7 months ago - Cutia Therapeutics Earnings release: H2 2025 - Filings